BRD-K98645985

  Cat. No.:  DC28337   Featured
Chemical Structure
1357647-78-9
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
BRD-K98645985 is a class of 12-membered macrolactam and a BAF transcriptional repression inhibitor with an EC50 of ~2.37 µM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, and without T cell activation or toxicity.
Cas No.: 1357647-78-9
Chemical Name: BRD-K98645985
Synonyms: BRDK98645985; BRD K98645985; BRD-K98645985
SMILES: O=C(NC1=CC=C(OC[C@H](C)N(CC2=CC=C(C3=NC=CC=C3)C=C2)C[C@H](C)[C@@H](OC)CN(C)C4=O)C4=C1)NC(C)C
Formula: C33H43N5O4
M.Wt: 573.73
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: BRD-K98645985 is a class of 12-membered macrolactam and a BAF (Brg/Brahma-associated factors) transcriptional repression inhibitor with an EC50 of ~2.37 µM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, and without T cell activation or toxicity[1].
Target: BAF transcriptional repression:2.37 μM (EC50) HIV-1
In Vitro: BRD-K98645985 (30 µM; 18 hours) treatment shows a 5-fold increase in Bmi1, 2.6-fold increase in Ring1, and 3.3-fold decrease in Fgf4[1]. BRD-K98645985 treatment shows a concentration dependent latency reversal in J-Lat T-cell line models. BRD-K98645985 can be combined with other LRAs to improve reservoir targeting[1].
References: [1]. Marian CA, et al. Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal. Cell Chem Biol. 2018 Dec 20;25(12):1443-1455.e14.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC70382 Elunonavir Elunonavir is an azapeptide atazanavir analogs useful for treating HIV infections.
DC47604 GPS491 GPS491 (EC50 = 0.47 μM) suppresses expression of the HIV-1 structural protein Gag and alters HIV-1 RNA accumulation, decreasing the abundance of RNAs encoding the structural proteins while increasing levels of viral RNAs encoding the regulatory proteins.
DC47230 Emivirine Emivirine is a non-nucleoside reverse transcriptase inhibitors (NNRTIs) that displays potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity.
DC44929 Cyclotriazadisulfonamide Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way.
DC28337 BRD-K98645985 BRD-K98645985 is a class of 12-membered macrolactam and a BAF transcriptional repression inhibitor with an EC50 of ~2.37 µM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, and without T cell activation or toxicity.
DC9475 Ritonavir Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS,showed potent activity against COVID-19(SARS-COV-2) .
DC10355 Nelfinavir Nelfinavir(AG-1341) is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection.
DC9476 NBD-556 NBD-556 is small molecule mimetic of CD4, NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding.
DC9308 Doravirine (MK-1439) Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor.
DC8908 Darunavir ethanolate Darunavir ethanolate is an HIV protease inhibitor,showed potent activity against COVID-19(SARS-COV-2).
X